NRC Form 374
(5-84)

U.S. NUCLEAR REGULATORY COMMISSION



Amendment No. 05

# MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 40 and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

| Licensee | In accordance with application dated June 5, 1984 |
|---|---|
| 1. Missoula Community Hospital | 3. License number 25-18361-01 is amended in its entirety to read as follows: |
| 2. 2827 Fort Missoula Road<br>Missoula, Montana 59801 | 4. Expiration date September 30, 1990 |
| | 5. Docket or Reference No. 030-14921 |

| 6. Byproduct, source, and/or special nuclear material | 7. Chemical and/or physical form | 8. Maximum amount that licensee may possess at any one time under this license |
|---|---|---|
| A. Any byproduct material listed in Groups I and II of Schedule A, Section 35.100 of 10 CFR 35 | A. Any radiopharmaceutical listed in Groups I and II of Schedule A, Section 35.100 of 10 CFR 35 | A. As necessary for uses authorized in Subitem 9.A. |
| B. Any byproduct material listed in Group III of Schedule A, Section 35.100 of 10 CFR 35 | B. Any form listed in Group III of Schedule A, Section 35.100 of 10 CFR 35 | B. 2 curies of each byproduct material authorized in Subitem 6.B. |
| C. Any byproduct material listed in Section 31.11(a) of 10 CFR 31 | C. Any | C. 5 millicuries of each byproduct material authorized in Subitem 6.C. |

**MATERIALS LICENSE**
SUPPLEMENTARY SHEET

License number: 25-18361-01
Docket or Reference number: 030-14921
Amendment No. 05

| | | |
|---|---|---|
| D. Iodine-131 | D. Any iodine that has been manufactured, labeled, packaged, and distributed in accordance with a specific license issued pursuant to Section 32.72 of 10 CFR 32 or a specific license issued to a manufacturer by an Agreement State pursuant to equivalent State Regulations. | D. 30 millicuries |

9. Authorized use

A. Any diagnostic procedure listed in Groups I and II of Schedule A, Section 35.100 of Title 10, Code of Federal Regulations.

B. Preparation and use of radiopharmaceuticals for any diagnostic procedure listed in Group III of Schedule A, Section 35.100 of Title 10, Code of Federal Regulations.

C. In vitro studies.

D. For treatment of hyperthyroidism, and cardiac dysfunction.

CONDITIONS

10. Licensed material shall be used only at the Missoula Community Hospital, 2827 Fort Missoula Road, Missoula, Montana.

11. The licensee shall comply with the provisions of Title 10, Chapter 1, Code of Federal Regulations, Part 19, "Notices, Instructions and Reports to Workers; Inspections" and Part 20, "Standards for Protection Against Radiation."

**MATERIALS LICENSE**
SUPPLEMENTARY SHEET

License number
25-18361-01

Docket or Reference number
030-14921

Amendment No. 05

12. Licensed material listed in Item 6 above is authorized for use by, or under the supervision of, the following individual(s) for the materials and uses indicated:

| | |
|---|---|
| Hugh C. Huntley, M.D. | Groups I, II, and III<br>In vitro studies<br>Iodine-131 as iodide for treatment of hyperthyroidism and cardiac dysfunction |
| David W. Burgan, M.D. | Groups I, II, and III<br>In vitro studies<br>Iodine-131 as iodide for treatment of hyperthyroidism and cardiac dysfunction |
| Thomas Andrew Layne, M.D. | Groups I, II, and III<br>In vitro studies<br>Iodine-131 as iodide for treatment of hyperthyroidism and cardiac dysfunction |
| Albert R. Ward, M.D. | Groups I, II, and III<br>In vitro studies<br>Iodine-131 as iodide for treatment of hyperthyroidism and cardiac dysfunction |
| Wesley E. Root, M.D. | Groups I, II, and III<br>In vitro studies<br>Iodine-131 as iodide for treatment of hyperthyroidism and cardiac dysfunction |

13. Licensed material shall be used in accordance with the provisions of Section 35.14(b)(c)(e) and (f) of Title 10, Code of Federal Regulations.

14. Notwithstanding the provision of 10 CFR 35.14, the licensee can receive byproduct materials from St. Patrick Hospital, 500 W. Broadway, Missoula, Montana, License Number 25-16773-02.

**MATERIALS LICENSE**
SUPPLEMENTARY SHEET

License number
25-18361-01

Docket or Reference number
030-14921

Amendment No. 05

15. For a period not to exceed 60 days in any calendar year, a visiting physician is authorized to use licensed material for human use under the terms of this license, provided the visiting physician:

    A. Has the prior written permission of the hospital's administrator and its Radiation Safety Committee, and

    B. Is specifically named as a user on a Nuclear Regulatory Commission license authorizing human use, and

    C. Performs only those procedures for which he is specifically authorized by a Nuclear Regulatory Commission license.

    The licensee shall maintain for inspection by the Commission, copies of the written permission specified in Subitem A above and of the license(s) specified in Subitems B and C above. These records shall be maintained for 5 years from the time the licensee grants its permission under Subitem A above.

16. The licensee is authorized to hold radioactive material with a physical half-life of less than 65 days for decay-in-storage before disposal in ordinary trash provided:

    A. Radioactive waste to be disposed of in this manner shall be held for decay a minimum of 10 half-lives.

    B. Prior to disposal as normal waste, radioactive waste shall be monitored to determine that its radioactivity cannot be distinguished from background with typical low-level laboratory survey instruments. All radiation labels will be removed or obliterated.

    C. Generator columns shall be segregated so that they may be monitored separately to ensure decay to background levels prior to disposal.

17. Except as specifically provided otherwise by this license, the licensee shall possess and use licensed material described in Items 6, 7, and 8 of this license in accordance with statements, representations, and procedures contained in application dated June 5, 1984, Model ALARA Program contained in Appendix O of Regulatory Guide 10.8 (Revision 1), "Guide for the Preparation of Applications for Medical Programs," October 1980; and letter dated August 7, 1985. The Nuclear Regulatory Commission's regulations shall govern the licensee's statements in applications or letters, unless the statements are more restrictive than the regulations.

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Original Signed By
Jack E. Whitten

Date SEP 10 1985

By _____
Nuclear Materials Safety Section
Region IV
Arlington, Texas 76011

Official Record Copy

MC40